NCT05507983

Tranexamic Acid During Excisional Burn Surgery

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Maasstad Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to access the efficacy of the drug tranexamic acid in reducing blood loss during burn excision surgery.

Detailed description

This study is a double-blinded, randomized placebo-controlled trial. After informed consent patients will be randomized in either the placebo or the tranexamic acid group (1500 mg). The intervention will be conducted during burn excisional surgery. First, the participant with be anesthetized, whereafter the study medication is administered.

Conditions

• Burns
• Blood Loss, Surgical
• Blood Loss
• Tranexamic Acid
• Burn Excisional Surgery

Interventions

Type	Name	Description
DRUG	Tranexamic acid	Tranexamic acid 1500 mg
DRUG	Placebo	Placebo, sodium chloride 0.9%

Timeline

• Start date: 2021-12-01
• Primary completion: 2025-01-01
• Completion: 2025-04-01
• First posted: 2022-08-19
• Last updated: 2024-03-13

Locations

3 sites across 1 country: Netherlands